Clinical, biological, and prognostic implications of SF3B1 co-occurrence mutations in very low/low- and intermediate-risk MDS patients
Sign Up to like & getrecommendations! Published in 2021 at "Annals of Hematology"
DOI: 10.1007/s00277-020-04360-4
Abstract: SF3B1 is a highly mutated gene in myelodysplastic syndrome (MDS) patients, related to a specific subtype and parameters of good prognosis in MDS without excess blasts. More than 40% of MDS patients carry at least… read more here.
Keywords: biological prognostic; clinical biological; mds patients; mds ... See more keywords
A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS
Sign Up to like & getrecommendations! Published in 2018 at "Leukemia"
DOI: 10.1038/s41375-018-0118-9
Abstract: Erythropoiesis-stimulating agents are first choice for treating anemia in low-risk MDS. This double-blind, placebo-controlled study assessed the efficacy and safety of epoetin-α in IPSS low- or intermediate-1 risk (i.e., low-risk) MDS patients with Hb ≤ 10.0 g/dL, with… read more here.
Keywords: risk; placebo controlled; low risk; placebo ... See more keywords
Genetic mutations associated with blood count abnormalities in myeloid neoplasms
Sign Up to like & getrecommendations! Published in 2022 at "Hematology"
DOI: 10.1080/16078454.2022.2094134
Abstract: ABSTRACT Introduction Myelodysplastic syndromes (MDS) predominantly present with varying degrees of cytopenia, while myelodysplastic syndromes/myeloproliferative neoplasms (MDS/MPN) exhibit proliferative features. Genetic defects underlying different complete blood count (CBC) alterations remain to be defined. Objective We… read more here.
Keywords: mds; mds mpn; risk mds; blood ... See more keywords
Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML
Sign Up to like & getrecommendations! Published in 2022 at "Blood Advances"
DOI: 10.1182/bloodadvances.2022007334
Abstract: Key points In the phase 3 PANTHER trial, EFS was similar between arms in the intent-to-treat population and in patients with higher-risk MDS. A signal for improved overall survival for pevonedistat+azacitidine was seen in higher-risk… read more here.
Keywords: risk mds; pevonedistat plus; higher risk; plus azacitidine ... See more keywords